98 related articles for article (PubMed ID: 16397044)
1. Motexafin-gadolinium taken up in vitro by at least 90% of glioblastoma cell nuclei.
De Stasio G; Rajesh D; Ford JM; Daniels MJ; Erhardt RJ; Frazer BH; Tyliszczak T; Gilles MK; Conhaim RL; Howard SP; Fowler JF; Estève F; Mehta MP
Clin Cancer Res; 2006 Jan; 12(1):206-13. PubMed ID: 16397044
[TBL] [Abstract][Full Text] [Related]
2. Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme.
Ford JM; Seiferheld W; Alger JR; Wu G; Endicott TJ; Mehta M; Curran W; Phan SC
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):831-8. PubMed ID: 17560737
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Motexafin gadolinium (MGd) as a contrast agent for intraoperative MRI.
Hirschberg H; Wu GN; Madsen SJ
Minim Invasive Neurosurg; 2007 Dec; 50(6):318-23. PubMed ID: 18210352
[TBL] [Abstract][Full Text] [Related]
4. Motexafin gadolinium: gadolinium (III) texaphyrin, gadolinium texaphyrin, Gd-Tex, GdT2B2, PCI 0120.
Drugs R D; 2004; 5(1):52-7. PubMed ID: 14725495
[TBL] [Abstract][Full Text] [Related]
5. MRI measurement of the uptake and retention of motexafin gadolinium in glioblastoma multiforme and uninvolved normal human brain.
Wu GN; Ford JM; Alger JR
J Neurooncol; 2006 Mar; 77(1):95-103. PubMed ID: 16547607
[TBL] [Abstract][Full Text] [Related]
6. Gadolinium neutron capture in glioblastoma multiforme cells.
Yasui LS; Andorf C; Schneider L; Kroc T; Lennox A; Saroja KR
Int J Radiat Biol; 2008 Dec; 84(12):1130-9. PubMed ID: 19061138
[TBL] [Abstract][Full Text] [Related]
7. Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors.
Khuntia D; Mehta M
Expert Rev Anticancer Ther; 2004 Dec; 4(6):981-9. PubMed ID: 15606327
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of motexafin gadolinium in adults with brain metastases or glioblastoma multiforme.
Miles DR; Smith JA; Phan SC; Hutcheson SJ; Renschler MF; Ford JM; Boswell GW
J Clin Pharmacol; 2005 Mar; 45(3):299-312. PubMed ID: 15703365
[TBL] [Abstract][Full Text] [Related]
9. Hypericin uptake: a prognostic marker for survival in high-grade glioma.
Ritz R; Müller M; Dietz K; Duffner F; Bornemann A; Roser F; Tatagiba M
J Clin Neurosci; 2008 Jul; 15(7):778-83. PubMed ID: 18394904
[TBL] [Abstract][Full Text] [Related]
10. Motexafin gadolinium: a novel radiosensitizer for brain tumors.
Francis D; Richards GM; Forouzannia A; Mehta MP; Khuntia D
Expert Opin Pharmacother; 2009 Sep; 10(13):2171-80. PubMed ID: 19640206
[TBL] [Abstract][Full Text] [Related]
11. Re-evaluating gadolinium(III) texaphyrin as a radiosensitizing agent.
Bernhard EJ; Mitchell JB; Deen D; Cardell M; Rosenthal DI; Brown JM
Cancer Res; 2000 Jan; 60(1):86-91. PubMed ID: 10646858
[TBL] [Abstract][Full Text] [Related]
12. Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme.
Chang JE; Khuntia D; Robins HI; Mehta MP
Clin Adv Hematol Oncol; 2007 Nov; 5(11):894-902, 907-15. PubMed ID: 18185489
[TBL] [Abstract][Full Text] [Related]
13. Motexafin gadolinium: a novel radiosensitizer for brain tumors.
Forouzannia A; Richards GM; Khuntia D; Mehta MP
Expert Rev Anticancer Ther; 2007 Jun; 7(6):785-94. PubMed ID: 17555388
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect.
Szentirmai O; Baker CH; Lin N; Szucs S; Takahashi M; Kiryu S; Kung AL; Mulligan RC; Carter BS
Neurosurgery; 2006 Feb; 58(2):365-72; discussion 365-72. PubMed ID: 16462491
[TBL] [Abstract][Full Text] [Related]
15. Intracellular localization of the radiation enhancer motexafin gadolinium using interferometric Fourier fluorescence microscopy.
Woodburn KW
J Pharmacol Exp Ther; 2001 Jun; 297(3):888-94. PubMed ID: 11356908
[TBL] [Abstract][Full Text] [Related]
16. Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria.
Günther HS; Schmidt NO; Phillips HS; Kemming D; Kharbanda S; Soriano R; Modrusan Z; Meissner H; Westphal M; Lamszus K
Oncogene; 2008 May; 27(20):2897-909. PubMed ID: 18037961
[TBL] [Abstract][Full Text] [Related]
17. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme.
Liu C; Sarkaria JN; Petell CA; Paraskevakou G; Zollman PJ; Schroeder M; Carlson B; Decker PA; Wu W; James CD; Russell SJ; Galanis E
Clin Cancer Res; 2007 Dec; 13(23):7155-65. PubMed ID: 18056196
[TBL] [Abstract][Full Text] [Related]
18. Photodynamic therapy of malignant glioma with hypericin: comprehensive in vitro study in human glioblastoma cell lines.
Ritz R; Wein HT; Dietz K; Schenk M; Roser F; Tatagiba M; Strauss WS
Int J Oncol; 2007 Mar; 30(3):659-67. PubMed ID: 17273767
[TBL] [Abstract][Full Text] [Related]
19. Progress in the use of gadolinium for NCT.
Cerullo N; Bufalino D; Daquino G
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S157-60. PubMed ID: 19410468
[TBL] [Abstract][Full Text] [Related]
20. Noninvasive and nondestructive optical spectroscopic measurement of motexafin gadolinium in mouse tissues: comparison to high-performance liquid chromatography.
Kanick SC; Eiseman JL; Joseph E; Guo J; Parker RS
J Photochem Photobiol B; 2007 Sep; 88(2-3):90-104. PubMed ID: 17604637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
